Popular terms

Bowel topics
Bowel Disease
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Inflammation
Mercaptopurine
Probiotics
Abdominal Pain
Discomfort
Bowel Movement
Gastrointestinal
Ulcerative Colitis
Rheumatoid Arthritis
Jejunal Tube
Spring Mechanism
Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Bowel patents

      

This page is updated frequently with new Bowel-related patent applications.




Date/App# patent app List of recent Bowel-related patents
08/18/16
20160237041 
 Fumarate compounds, pharmaceutical compositions thereof, and methods of use patent thumbnailFumarate compounds, pharmaceutical compositions thereof, and methods of use
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

08/18/16
20160235872 
 Compositions and methods to image and quantify inflammation patent thumbnailCompositions and methods to image and quantify inflammation
Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
Celsense, Inc.


08/18/16
20160235813 
 Anti-inflammatory proteins and methods of use patent thumbnailAnti-inflammatory proteins and methods of use
A method and composition for reducing or alleviating inflammation in a subject is provided, including administering to the subject a therapeutically effective amount; of one or more isolated proteins respectively comprising an amino acid sequence set forth in seq id nos:1-31, or a biologically active fragment or variant thereof or combinations of these to thereby reduce or alleviate inflammation. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease..
James Cook University


08/18/16
20160235701 
 Composition and methods for treating intestinal hyperpermeability patent thumbnailComposition and methods for treating intestinal hyperpermeability
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

08/18/16
20160235683 
 Amorphous magnesium-substituted calcium phosphate compositions and their uses patent thumbnailAmorphous magnesium-substituted calcium phosphate compositions and their uses
Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.. .
Medical Research Council


08/11/16
20160230174 
 Tolerogenic dendritic cells to treat inflammatory bowel disease patent thumbnailTolerogenic dendritic cells to treat inflammatory bowel disease
Methods are disclosed herein for treating or preventing an inflammatory bowel disease in a subject. These methods include administering to a subject an effective amount of tolerogenic dendritic cells, wherein the tolerogenic dendritic cells comprise at least one of an antisense compound specific for cd40, and antisense compound specific for cd80 and an antisense compound specific for cd86..
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


08/11/16
20160229905 
 Modified anti-inflammatory proteins and  use patent thumbnailModified anti-inflammatory proteins and use
A modified ac-tmp-2 protein lacks one or a plurality of acidic c-terminal amino acids normally present in a full-length or wild-type ac-tmp-2 protein and may also lack one or a plurality of n-terminal amino acids while retaining the amino acid sequence c—s—c at or near the n-terminus. The modified ac-tmp-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject.
James Cook University


08/11/16
20160229819 
 Fumarate compounds, pharmaceutical compositions thereof, and methods of use patent thumbnailFumarate compounds, pharmaceutical compositions thereof, and methods of use
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

08/11/16
20160228474 
 Method for producing amniotic mesenchymal stromal cell composition,  cryopreserving the same, and therapeutic agent patent thumbnailMethod for producing amniotic mesenchymal stromal cell composition, cryopreserving the same, and therapeutic agent
An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived mscs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis..
Kaneka Corporation


08/04/16
20160224753 
 Systems and methods for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia patent thumbnailSystems and methods for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia
Systems and methods are disclosed for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel or generating a risk score for risk of disease for the patient's bowel, based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel..
Heartflow, Inc.


08/04/16
20160222383 

Antisense compositions and methods of making and using same


The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against smad7. The pharmaceutical formulations can be used to treat crohn's disease, ulcera-five colitis and chronic inflammatory bowel disease..
Nogra Pharma Limited


08/04/16
20160220620 

Probiotic compositions for use in the treatment of bowel diseases


The present disclosure is directed to methods of administering and compositions comprising lactobacillus plantarum cect 7478, lactobacillus plantarum cect 7485, and pediococcus acidilactici cect 7483 or a mutant or variant thereof. The compositions and methods are useful in the probiotic treatment of bowel diseases or conditions such as inflammatory bowel disease, irritable bowel syndrome, and abdominal distension and bloating..
Ab-biotics S.a.


08/04/16
20160220193 

Systems and methods for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia


Systems and methods are disclosed for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel or generating a risk score for risk of disease for the patient's bowel, based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel..
Heartflow, Inc.


08/04/16
20160219947 

Halter bib athletic garment


A halter bib athletic garment is described herein. A halter bib athletic garment may be removed or lowered without removing a jersey by simply pulling a halter strap over the head of a wearer.
Bell Sports, Inc.


07/28/16
20160213739 

Treatments for disorders using guanylate cyclase c agonists


The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (ibd), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (bph), pain, salt retention or fluid retention.. .
Ironwood Pharmaceuticals, Inc


07/21/16
20160208329 

Systems, devices and methods for anti-tl1a therapy


The present invention relates to biomarker genes for diagnosing and treating diseases. Provided herein are systems and methods of diagnosing a disease in a patient based on the patient's expression levels of biomarker genes.
Cedars-sinai Medical Center


07/21/16
20160206707 

Lactoferrin for the treatment of ibd associated with bacterial invasion


The present invention relates to a substance and an oral formulation for modified release dosage for use in the treatment of inflammatory bowel disease due to escherichia coli invasion.. .
Giellepi S.p.a.


07/21/16
20160206686 

Treatment of constipation-predominant irritable bowel syndrome


The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.. .
Forest Laboratories Holdings Limited


07/21/16
20160206650 

Methods and compositions for bowel cleansing before a medical procedure


Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as ct colography.. .
The General Hospital Corporation


07/21/16
20160206578 

Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use


The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited


07/21/16
20160206564 

Compositions and methods for treatment and prophylaxis of gastrointestinal diseases


Methods and compositions for treating inflammatory bowel disease, irritable bowel syndrome, and travelers' diarrhea involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic.

07/14/16
20160200789 

Il4 conjugated to antibodies against extracellular matrix components


A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


07/14/16
20160200766 

Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders


The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.


07/14/16
20160199410 

Oral rehydration solution


Provided herein are oral rehydration compositions useful for treating a dehydrated subject. Exemplary compositions provided herein are oral rehydration compositions customized for use with children, athletes, and subjects having short bowel syndrome.
Mayo Foundation For Medical Education And Research


07/14/16
20160199052 

Organ retractor


A medical device of the present invention includes one or more anchors and an elongated member. Advantageously, the elongated member may be coupled to the anchors.

07/14/16
20160199020 

Bowel sound analysis method and system


A bowel sound analysis method and system utilizes an audio collection apparatus to continuously monitor an abdominal cavity of an examinee and collect a bowel sound signal of an intestinal tract inside the abdominal cavity, converts the bowel sound signal into a digital signal, then removes noise from the digital signal by using higher-order statistics (hos) and captures a high-complexity feature from the digital signal by using fractal dimension algorithm, and subsequently defines the high-complexity feature as an intestinal motility signal. The refore, according to the intestinal motility signal, a time point when intestinal motility occurs in the intestinal tract inside the abdominal cavity of the examinee can be learned, and bowel sound features such as the amplitude, frequency, and period of the intestinal motility signal may further be analyzed to determine a health condition of the intestinal tract..
Chimei Medical Center


07/14/16
20160198935 

Apparatus and fixing and shortening bowel at the time of endoscopy


Disclosed are a device and method for fixing and shortening the bowel at the time of endoscopy. The device and method can improve the shortening efficiency of the bowel when compared with the existing endoscope surgery, reduce the inspection time, and mitigate patient inconvenience.

07/07/16
20160193469 

Neuromodulation system and related methods


Embodiments of the present invention describe a system and method of stimulating nerves during a medical procedure including positioning one or more electrodes in electrical contact with one or more nerves of a patient and electrically stimulating the one or more nerves during a lower urinary, rectal or medical procedure affecting the bowel sufficient to affect one or more of bladder activity, prostate function, incontinence, or pain.. .
Urologix, Llc


07/07/16
20160193343 

Composition for use in treating and preventing inflammation related disorder


The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
Aihol Corporation


07/07/16
20160193268 

Andrographis paniculata extract


An extract of andrographis particulata extract containing andrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysaccharides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease..
Nutrition Science Partners Limited


07/07/16
20160193180 

Composition for preventing and treating immune diseases containing daurinol compound as active ingredient


The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of il-17 and tnf-α, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive t cells and increasing regulatory t cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the mongolian medicinal plant haplophyllum dauricum or haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases..
The Catholic University Of Korea Industry-academic Cooperation Foundation


07/07/16
20160193169 

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

06/30/16
20160185849 

Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease


Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..

06/23/16
20160178644 

Methods for diagnosing and treating inflammatory bowel disease


Biomarkers for diagnosing inflammatory bowel disease, including crohn's disease, including fibrotic or fibrostenotic crohn's disease, and ulcerative colitis and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and crohn's disease, including fibrotic or fibrostenotic crohn's disease, are provided..

06/23/16
20160177306 

Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field


The invention relates to antisense oligonucleotidic sequences (odn) against smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as crohn's disease and ulcerative colitis.. .

06/23/16
20160176816 

Novel biphenyl derivative and preparing same


The present invention provides novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, methods for preparing the same, and a pharmaceutical composition containing the same. The novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, as disclosed in the present invention, act as muscarinic m3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes..

06/23/16
20160175491 

Local drug delivery devices and methods for treating cancer


Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site..

06/23/16
20160175382 

Compositions and methods for inducing urinary voiding and defecation


Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time.

06/23/16
20160175368 

Legume/grain based food product with prebiotic/probiotic source


A minimally processed ready-to-eat legume/grain product is provided containing a significant amount of probiotic fiber and a probiotic source or is consumed with a probiotic source for the prevention and/or treatment of inflammatory chronic conditions such as inflammatory, autoimmune chronic conditions such as irritable bowel syndrome (ibs), digestive disorders such chronic constipation, gastric acid reflux, diabetes, heart disease, obesity, some type of cancer, malabsorptive disorders, eczema as well mental health disorders such as anxiety disorder. The present invention is suitable for men and woman of all ages..

06/23/16
20160175253 

Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and preparation thereof


The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.. .



Bowel topics: Bowel Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Inflammation, Mercaptopurine, Probiotics, Abdominal Pain, Discomfort, Bowel Movement, Gastrointestinal, Ulcerative Colitis, Rheumatoid Arthritis, Jejunal Tube, Spring Mechanism, Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3302

5187

2 - 1 - 103